혈장요법 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global plasma therapy market size is expected to reach USD 1.92 Billion in 2034 from USD 0.56 Billion in 2025, growing at a CAGR of 14.64% during 2026-2034.The global plasma therapy market has gained attention due to its potential use in treating various medical conditions and infectious diseases. Plasma therapy involves using plasma obtained from recovered patients or donors to provide antibodies that help fight infections. This approach has been explored as a treatment option in several viral disease outbreaks and immune-related conditions.

Several factors are driving the development of the plasma therapy market. Advances in immunology and blood plasma research have improved understanding of antibody-based treatments. Healthcare institutions and research organizations are exploring plasma therapy as part of broader therapeutic strategies. Increased research funding and global collaboration have also supported clinical investigations in this field.

In the future, the plasma therapy market is expected to evolve as research continues to explore its medical applications. Improved plasma collection and processing technologies will enhance treatment availability. As medical science advances in immunotherapy and antibody treatments, plasma-based therapies may play a supporting role in certain healthcare treatments.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Pure PRP
• Leucocyte-rich PRP
• Pure Platelet-rich Fibrin (PRF)
• Leukocyte-rich Fibrin (L-PRF)

By Source

• Autologous
• Allogenic

By Application

• Orthopedics
• Dermatology
• Dental
• Cardiac Muscle Injury
• Nerve Injury
• Others

By End User

• Hospitals & Clinics
• Research Institutions

COMPANIES PROFILED

• Takeda Pharmaceutical Company Limited, CSL Limited, Grifols S.A., Octapharma AG, Biotest AG, Bio Products Laboratory Ltd., Kedrion Biopharma Inc., ADMA Biologics, Inc., SK Plasma Co., Ltd., Kamada Ltd., LFB S.A., GC Biopharma Corp., Hualan Biological Engineering Inc., Shanghai RAAS Blood Products Co., Ltd., China Biologic Products Holdings, Inc., Sanquin, Terumo Blood and Cell Technologies, Baxter International Inc., Prothena Biosciences Limited, Japan Blood Products Organization

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PLASMA THERAPY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Pure PRP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Leucocyte-rich PRP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Pure Platelet-rich Fibrin (PRF) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Leukocyte-rich Fibrin (L-PRF) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PLASMA THERAPY MARKET: BY SOURCE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Source
• 5.2. Autologous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Allogenic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PLASMA THERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Orthopedics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Dental Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Cardiac Muscle Injury Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Nerve Injury Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PLASMA THERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PLASMA THERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type
  • 8.2.2 By Source
  • 8.2.3 By Application
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type
  • 8.3.2 By Source
  • 8.3.3 By Application
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type
  • 8.4.2 By Source
  • 8.4.3 By Application
  • 8.4.4 By End User
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type
  • 8.5.2 By Source
  • 8.5.3 By Application
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type
  • 8.6.2 By Source
  • 8.6.3 By Application
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PLASMA THERAPY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Takeda Pharmaceutical Company Limited
  • 10.2.2 CSL Limited
  • 10.2.3 Grifols S.A
  • 10.2.4 Octapharma AG
  • 10.2.5 Biotest AG
  • 10.2.6 Bio Products Laboratory Ltd
  • 10.2.7 Kedrion Biopharma Inc
  • 10.2.8 ADMA BiologicsInc
  • 10.2.9 SK Plasma Co.Ltd
  • 10.2.10 Kamada Ltd
  • 10.2.11 LFB S.A
  • 10.2.12 GC Biopharma Corp
  • 10.2.13 Hualan Biological Engineering Inc
  • 10.2.14 Shanghai RAAS Blood Products Co.Ltd
  • 10.2.15 China Biologic Products HoldingsInc
  • 10.2.16 Sanquin
  • 10.2.17 Terumo Blood And Cell Technologies
  • 10.2.18 Baxter International Inc
  • 10.2.19 Prothena Biosciences Limited
  • 10.2.20 Japan Blood Products Organization